TITLE

Assumptions kill

AUTHOR(S)
Miller, Saul
PUB. DATE
April 2013
SOURCE
British Journal of General Practice;Apr2013, Vol. 63 Issue 609, p213
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In this article, the author focuses on the changes occurred in drug and big pharmaceutical companies. He mentions that currently companies were spending large amount of sales revenues on marketing as compared to research and development sector. He mentions several assumptions which include development of ten biggest drug companies, centralized formulary decision and belief in market forces.
ACCESSION #
86439529

 

Related Articles

  • Surging demand for specialty Rx may be problematic for retail. Frederick, Jim // Drug Store News;8/13/2007, Vol. 29 Issue 10, p48 

    The article reports on various opportunities and major challenges faced by retail pharmacies given the growth of specialty and bio-engineered drugs in the U.S. The future of pharmacies will rely on how the industry adapts to the new era of biotechnology-based research and development. However,...

  • Drug industry research outlays plummet. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/7/2012, Vol. 184 Issue 11, pE596 

    The article focuses on the annual report of the Patented Medicines Price Review Board (PMPRB) which states that despite the increase in revenue of the drug industry in Canada in 2011, the research and development (R&D) outlays declined to 15.8 percent to a level not seen in over a decade. The...

  • It Will All End In Tiers. Booth, Rupert // Life Science Today;Apr/May2002, Vol. 3 Issue 2, p10 

    Focuses on the issues raised at the pharmaceutical industry conference BioPharMOS in Monte Carlo, Monaco. Problems related to supply volume; Prioritization of marketing and research and development; Revision of information systems.

  • Drug Supply Shortages in Clinical Trials. Burns, John // Contract Pharma;Nov/Dec2014, Vol. 16 Issue 9, p71 

    The article discusses issues in the field of new drugs research and development (R&D) in the pharmaceutical industry as of late 2014, particularly the effects of drug supply shortages in clinical trials. Among the major adverse effects of shortages are lowered enrollment, budget increases, and...

  • Evaluating China's Supply Chain. Van Arnum, Patricia // Pharmaceutical Technology;Aug2013 Supplement, ps30 

    The article discusses the increased globalization and pharmaceutical industry in context of revenue and supply chain. It mentions that for pharmaceuticals 40 percent of finished drugs in the U.S. comes from overseas. It mentions about Steven Solomon, associate director for global operations and...

  • Pharmerging Markets Expected to Ramp Up Medication Volume.  // Chain Drug Review;12/7/2015, Vol. 37 Issue 20, p76 

    The article focuses on the IMS Institute for Healthcare Informatics' report about the global use of medicines which reveals that most of the global increase in the volumes of medicines used in the five years to 2020 will be in countries such as India, China, Brazil, Indonesia, and Africa.

  • Neglected still. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/7/2012, Vol. 184 Issue 11, pE598 

    The article discusses a report by the Médecins Sans Frontières (MSF) focuses on the impact of several obstacles including inadequate drug supply, shortage of rapid diagnostic tests, and pharmaceutical industry indifference on the prevalence of 17 "neglected" diseases of the world.

  • Pharmacy fired up over handling of NRT listing. Doyle, Janet // Australian Journal of Pharmacy;Apr2011, Vol. 92 Issue 1091, p4 

    The article reports on the shortage of subsidised nicotine replacement therapy (NRT) supply in the pharmaceutical industry in Australia. Some manufacturers are trying to meet the spike in demand by supplying retail packs at a cost to itself. Industry sources have alleged that the timing and...

  • Dynamic Changes Coming to a Pharmacy Near You. Hallahan, Mary // Pharmaceutical Executive;Sep2000, Vol. 20 Issue 9, p137 

    Deals with the problems facing the pharmaceutical industry in the United States as of September 2000. Shortage of pharmacists; Expiration of patents of brand medications; Pressure on pharmacists brought by the aging population.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics